Navigation Links
New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes

MILAN, Italy, June 15 /CNW/ - Today AMADEO, one of the first studies to compare the protective potential of two angiotensin receptor blockers in hypertensive patients with diabetic nephropathy, was presented at the European Society of Hypertension, Milan. The results from this study show that telmisartan reduces proteinuria to a significantly greater extent than losartan.(1)

Commenting on the results, Prof. Ellen Burgess, Foothills Hospital in Calgary, Canada said "The AMADEO results are encouraging for an increasing number of patients with type 2 diabetes because they suggest that telmisartan could improve renoprotection. It is particularly interesting that the observed effect was seen despite the study being controlled for blood pressure." She continued, "telmisartan has already shown superior blood pressure lowering compared to losartan and, in AMADEO, patients were allowed to take other medication, if needed, to ensure similar blood pressure in both treatment groups. This suggests that the protective benefits seen with telmisartan here are an additional attribute beyond its established blood pressure lowering effects."

Diabetic nephropathy is a kidney disease that occurs in approximately one third of patients with diabetes mellitus(2). These study results could, therefore, have a positive impact on millions of type 2 diabetes patients as well as healthcare systems worldwide. The prevalence of diabetes is projected to increase at an alarming rate from 171 million in 2000 to 366 million by 2030(3), with the upsurge in obesity closely linked to increased type 2 diabetes. Over time, diabetic nephropathy can lead to end-stage renal disease, a serious condition that needs dialysis and increased medical care and resources. End-stage renal disease has tripled in prevalence over the past two decades(4) and has huge associated healthcare costs, predicted to be US$28 billion by 2010 in the US alone(5).
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:10/10/2008)...0 /- Inverness Medical,Inno... near-patient,diagnostics, monitoring and health m...n, the Secretary-General of the United Nations, as... of the world,s leading,research-based and generic...s, together with senior officials from the United ...
(Date:10/9/2008)...reased Sales and Marketing Efforts to Accelerate ...tem, MENLO PARK, Calif., Oct. 9 /- E...ces for the percutaneous repair of cardiac valves,...am with the appointment of,Sean Cleary as senior v...,Chris Richardson, as vice president of sales., "...
(Date:10/8/2008)... Animal Use in Cosmetics and Chemicals Testing, A... today announced,that results of a recently comple...lidation study on MatTek,s EpiDerm in vitro human ...ted the required sensitivity and,specificity for E...o animal,testing for determining human skin irrita...
(Date:10/8/2008)...o evaluate TAXUS(R) Element(TM) Platinum Chromium ...ss., Oct. 8 /- Boston Scien...at it has completed enrollment in,the PERSEUS tria...tion,TAXUS(R) Element(TM) paclitaxel-eluting coron...ed nearly 1,500 patients at 100 U.S. and,internati...
Breaking Medicine Technology:Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 2Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 3Evalve Expands Executive Leadership Team 2Evalve Expands Executive Leadership Team 3MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Best Practice Database Supports Bio Pharma M 26A Integration with New Publication 21393 1Best Practice Database Supports Bio Pharma M 26A Integration with New Publication 21393 2Golf cart injuries on the rise 21391 1Golf cart injuries on the rise 21391 2Video 3A The Nevada Division of Insurance Launches 2008 Health Sham Insurance Campaign 21390 1Video 3A The Nevada Division of Insurance Launches 2008 Health Sham Insurance Campaign 21390 2Video 3A The Nevada Division of Insurance Launches 2008 Health Sham Insurance Campaign 21390 3N Y Mets Omar Minaya Recognized at National Brain Cancer Organizations 3rd Annual Gala 21385 1N Y Mets Omar Minaya Recognized at National Brain Cancer Organizations 3rd Annual Gala 21385 2
...ion Pharmaceuticals Inc.,(TSX: TLN) announced toda...al trial investigating ECO-4601 in advanced cancer...f the American,Society of Clinical Oncology (ASCO)... I dose escalation portion of the study, 14,patien...one,glioma), that had completed and not responded ...
...- Imprime PGG(TM), an,investigational new drug fro...response, increases the effectiveness of Avastin(R... new preclinical,research presented yesterday at t...al Meeting in Chicago., Researchers at the Brown C...studied the synergistic effects of Imprime,PGG in ...
Other Medicine Technology:Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 2Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 3Biothera's Imprime PGG Enhanced Effectiveness of Avastin in Cancer,Study 2
(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
...e of the African naked mole-rat is helping scienti...in humans. Mole-rats are blind, hairless, and li...led over by a queen. In a new study, scientists, ...atures, are hoping to learn more about how stress ...
...ened to nationalise private hospitals if their own... a nationally televised speech, saying that the pr...part of the public health service if they failed t...e also described costs at private clinics as a sym...
... the knot-like structure of enzymes, but theyve be... an understanding of function what the enzyme act...drug discovery, since many of the most successful .... Now, in an expedited article in NATURE, research...
...ped by methane gas is commonplace in developing co... West too. Fiver persons fell victims to the deadl...arm in Shenandoah Valley, Virginia, US Monday even...34, a Mennonite farmer who climbed into the pit to...
Other Medicine News:Health News:Strange Sex Life of Mole-rats may Provide Clues About Human Infertility 2Health News:Translating Structure into Function 2Health News:Five Killed by Methane Gas on Virginia Farm 2Health News:Five Killed by Methane Gas on Virginia Farm 3
The Affinity pacemaker family offers some of today's smallest, truly automatic devices. Featuring the most effective combination of advanced technologies ever seen, the Affinity DR pacemaker incorpor
Innovative new tools for more efficient patient management begin when the pacemaker is implanted. These sophisticated tools are in effect each day, and they help automate follow-up tasks.
The first-ever completely automatic pacemaker, EnPulse offers exclusive features that make it sophisticated yet simple to use. It performs a wide range of diagnostic tests on a regular basis, without
...ystem 3000Dx (GCS3000Dx) is the first microarray i...oratories. The system consists of the FS450Dx Flui...g and staining of the array, the GCS3000Dx Scanner...croarrays to be scanned without operator intervent...
Medicine Products: